| Identification | More | [Name]
Betaxolol hydrochloride | [CAS]
63659-19-8 | [Synonyms]
1-[4-[2-(CYCLOPROPYLMETHOXY)ETHYL]PHENOXY]-3-ISOPROPYLAMINO-2-PROPANOL HYDROCHLORIDE
BETAXOLOL CHLOROHYDRATE
BETAXOLOL HCL
BETAXOLOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE MONOHYDRATE
SL 75212
(+-)-1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)-2-propano
1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-isopropylaminopropan-2-olhydroc
betoptic
kerlone
sl75212-10
sl-d.212
1-(isopropylamino)-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propan-2-ol hydrochloride
Betaxolo
2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-, hydrochloride
Betoptima
1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol hydrochloride
Kerlon | [EINECS(EC#)]
264-384-3 | [Molecular Formula]
C18H30ClNO3 | [MDL Number]
MFCD00242959 | [Molecular Weight]
343.89 | [MOL File]
63659-19-8.mol |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Melting point ]
116° | [storage temp. ]
2-8°C | [solubility ]
H2O: 36 mg/mL, soluble
| [form ]
solid
| [color ]
white
| [Water Solubility ]
Soluble to 50 mM in water | [Merck ]
14,1182 | [Stability:]
Hygroscopic | [Major Application]
pharmaceutical (small molecule) | [InChI]
InChI=1S/C18H29NO3.ClH/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16;/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3;1H | [InChIKey]
CHDPSNLJFOQTRK-UHFFFAOYSA-N | [SMILES]
C1(OCC(O)CNC(C)C)C=CC(CCOCC2CC2)=CC=1.Cl | [CAS DataBase Reference]
63659-19-8(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed. | [WGK Germany ]
3
| [RTECS ]
UA9823000
| [HS Code ]
2922504500 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral | [Toxicity]
LD50 in mice (mg/kg): 944 orally; 37 i.v. (Manoury) |
| Hazard Information | Back Directory | [Description]
Betaxolol hydrochloride is a cardioselective β-adrenergic blocker, reportedly devoid
of intrinsic sympathomimetic and membrane stabilizing properties. Its long
duration of action permits once-daily dosing in mild to moderate hypertension. It
is also being evaluated in glaucoma. | [Chemical Properties]
White or almost white, crystalline powder. | [Originator]
Synthelabo (France) | [Uses]
antifungal | [Definition]
ChEBI: The hydrochloride salt of betaxolol. | [Brand name]
Betoptic (Alcon); Kerlone (Sanofi Aventis). | [Biological Activity]
Selective β 1 -adrenoceptor antagonist. | [storage]
Store at -20°C | [References]
[1] SEUNG-WOON MYUNG Cheon H J. Gas chromatograph–mass spectrometric method for the determination of carvedilol and its metabolites in human urine[J]. Journal of Chromatography B, 2005, 822 1: Pages 70-77. DOI: 10.1016/j.jchromb.2005.05.023
[2] PANKAJ GUPTA R G. Amino Functionalized Graphene Oxide and Polymer Nanocomposite Based Electrochemical Platform for Sensitive Assay of Anti-Doping Drug Atenolol in Biological Fluids[J]. Journal of The Electrochemical Society, 2016, 163 1. DOI: 10.1149/2.0281613jes
[3] A WELLSTEIN G G B D Palm. Affinity and selectivity of beta-adrenoceptor antagonists in vitro.[J]. Journal of Cardiovascular Pharmacology, 1986, 8 Suppl 11: S36-40. DOI: 10.1097/00005344-198511001-00006
[4] DOROTA POZAROWSKA Zbigniew D Piotr Pozarowski. Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells?[J]. Cytometry Part B: Clinical Cytometry, 2009, 78B 2: 130-137. DOI: 10.1002/cyto.b.20493
[5] N. SHARIF. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes.[J]. Journal of Ocular Pharmacology and Therapeutics, 2001, 26 1: 305-317. DOI: 10.1089/108076801753162726
[6] GLYN CHIDLOW Neville N O José Melena. Betaxolol, a β1-adrenoceptor antagonist, reduces Na+ influx into cortical synaptosomes by direct interaction with Na+ channels: comparison with other β-adrenoceptor antagonists[J]. British Journal of Pharmacology, 2009, 130 4: 759-766. DOI: 10.1038/sj.bjp.0703369 |
|
|